Illumina Inks Dx Pact with DeCode, Promises More As Biopharma Opts to Bring Genotyping In House | GenomeWeb

Illumina and DeCode Genetics this week announced that they plan to co-develop and commercialize DNA-based diagnostics in several major disease areas.

According to the firms, the partnership will use Illumina's platform for high-multiplex SNP-genotyping to develop diagnostics for gene variants that DeCode has shown to be risk factors for developing diseases such as type II diabetes, myocardial infarction, and breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.